Translational biomarkers in the era of precision medicine.

Artificial intelligence Big data Clinical trials Omics Translational biomarkers

Journal

Advances in clinical chemistry
ISSN: 2162-9471
Titre abrégé: Adv Clin Chem
Pays: United States
ID NLM: 2985173R

Informations de publication

Date de publication:
2021
Historique:
entrez: 28 5 2021
pubmed: 29 5 2021
medline: 24 8 2021
Statut: ppublish

Résumé

In this chapter we discuss the past, present and future of clinical biomarker development. We explore the advent of new technologies, paving the way in which health, medicine and disease is understood. This review includes the identification of physicochemical assays, current regulations, the development and reproducibility of clinical trials, as well as, the revolution of omics technologies and state-of-the-art integration and analysis approaches.

Identifiants

pubmed: 34044910
pii: S0065-2423(20)30091-3
doi: 10.1016/bs.acc.2020.08.002
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-232

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Laura Bravo-Merodio (L)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

Animesh Acharjee (A)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom; NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospital Birmingham, Birmingham, United Kingdom. Electronic address: a.acharjee@bham.ac.uk.

Dominic Russ (D)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

Vartika Bisht (V)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

John A Williams (JA)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Medical Research Council Harwell Institute, Harwell Campus, Oxfordshire, United Kingdom.

Loukia G Tsaprouni (LG)

Birmingham City University, Centre for Life and Sport Science, Birmingham, United Kingdom.

Georgios V Gkoutos (GV)

Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom; Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom; NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospital Birmingham, Birmingham, United Kingdom; MRC Health Data Research UK (HDR UK), London, United Kingdom; NIHR Experimental Cancer Medicine Centre, Birmingham, United Kingdom; NIHR Biomedical Research Centre, University Hospital Birmingham, Birmingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH